Bio-Techne Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission, reporting condensed consolidated financial results for its fiscal first quarter.

Key Highlights

  • Net sales: $299,712 thousand for the quarter ended September 30, 2026, compared with $286,555 thousand in the prior-year quarter.
  • Net earnings: $28,293 thousand, down from $38,185 thousand in the same quarter of the prior year.
  • Diluted earnings per share: $0.18, compared with $0.24 in the prior-year quarter.
  • Operating income: $36,603 thousand, versus $47,658 thousand in the prior-year quarter, with selling, general and administrative expenses rising to $133,679 thousand from $116,213 thousand.
  • Cash and cash equivalents: $350,036 thousand at September 30, 2026, up from $264,712 thousand at June 30, 2026.
  • Shares outstanding: 157,090,727 shares of common stock as of November 2, 2026.
  • Short-term debt: $200,000 thousand reclassified to current liabilities at September 30, 2026, compared with $200,000 thousand in long-term debt at June 30, 2026.

Bio-Techne Reports Higher Sales but Lower Earnings in September 2026 Quarter

According to the filing, Bio-Techne Corporation (NASDAQ:TECH) reported net sales of $299,712 thousand for the quarter ended September 30, 2026, an increase from $286,555 thousand in the comparable prior-year period. Gross margin rose to $196,623 thousand from $188,112 thousand. However, the company disclosed that total operating expenses climbed to $160,020 thousand from $140,454 thousand, driven primarily by selling, general and administrative expenses of $133,679 thousand, up from $116,213 thousand a year earlier. Research and development costs also increased to $26,341 thousand from $24,241 thousand.

The filing reported operating income of $36,603 thousand, down from $47,658 thousand in the prior-year quarter. After other expense of $1,910 thousand (compared with other income of $333 thousand in the prior year) and income taxes of $6,400 thousand, net earnings were $28,293 thousand, versus $38,185 thousand a year ago. Basic earnings per share were $0.18 and diluted earnings per share were $0.18, compared with $0.25 basic and $0.24 diluted in the prior-year quarter. Weighted average diluted shares outstanding were 157,928 thousand.

On the balance sheet, the company disclosed total assets of $2,636,820 thousand at September 30, 2026, compared with $2,586,726 thousand at June 30, 2026. Cash and cash equivalents grew to $350,036 thousand from $264,712 thousand, supported by net cash provided by operating activities of $73,113 thousand. The filing noted that $200,000 thousand of debt obligations, carried as long-term at June 30, 2026, is now classified as short-term debt at September 30, 2026. Total shareholders' equity was $2,165,689 thousand at quarter end. During the quarter, the company paid cash dividends of $12,559 thousand and received $36,180 thousand from stock option exercises.

What Was Disclosed

Bio-Techne filed its quarterly report covering the period ended September 30, 2026, disclosing condensed consolidated income statements, balance sheets, and cash flow statements, along with notes on segments, restructuring, debt, leases, and subsequent events.